Table of Contents

company-logo

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Medicenna Therapeutics Dividend Announcement

• Medicenna Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Medicenna Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Medicenna Therapeutics Dividend History

Medicenna Therapeutics Dividend Yield

Medicenna Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Medicenna Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Medicenna Therapeutics Financial Ratios

P/E ratio-5.81
PEG ratio-0.38
P/B ratio6.66
ROE-149.65%
Payout ratio0.00%
Current ratio9.43
Quick ratio9.43
Cash Ratio8.85

Medicenna Therapeutics Dividend FAQ

Does Medicenna Therapeutics stock pay dividends?
Medicenna Therapeutics does not currently pay dividends to its shareholders.
Has Medicenna Therapeutics ever paid a dividend?
No, Medicenna Therapeutics has no a history of paying dividends to its shareholders. Medicenna Therapeutics is not known for its dividend payments.
Why doesn't Medicenna Therapeutics pay dividends?
There are several potential reasons why Medicenna Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Medicenna Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Medicenna Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Medicenna Therapeutics a dividend aristocrat?
Medicenna Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Medicenna Therapeutics a dividend king?
Medicenna Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Medicenna Therapeutics a dividend stock?
No, Medicenna Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Medicenna Therapeutics stocks?
To buy Medicenna Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Medicenna Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.